PATENT APPLICATIONS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:)
COX, III, George N. and DOHERTY, Daniel H.) <u>PRELIMINARY AMENDMENT</u>)
Int'l. Serial No.: PCT/US00/19336	"EXPRESS MAIL" MAILING LABEL NUMBER: EL822582809US DATE OF DEPOSIT:
Int'l. Filing Date: 13 July 2000	I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE TEXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
Priority Date: 13 July 1999	UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO THE ASSISTANT COMMISSIONER FOR PATENTS, BOX PCT, WASHINGTON, D.C. 20231.
For: "IMMUNOGLOBULIN FUSION PROTEINS") TYPED OR PRINTED NAME:
Atty. File No.: 4152-3-PUS) SIGNATURE: MICE MUSICAL)
Box PCT	
Assistant Commissioner for Patents	
Washington, D.C. 20231	

Dear Sir:

Prior to the initial review of the above-identified patent application by the Examiner, please enter the following Preliminary Amendment. Fees for this Preliminary Amendment are calculated and included with the Transmittal Letter accompanying this Amendment. Please charge any underpayment or debit any overpayment to Deposit Account 19-1970.

Please amend the above-identified patent application as follows:

IN THE SPECIFICATION:

Please replace the paragraph on page 22, lines 14-21, with the following paragraph:

--GF-IgG fusion proteins in which the 7 amino acid linker [ser-gly-gly-ser-gly-gly-ser] (SEQ

ID NO:3) that fuses the GF to the IgG domain is eliminated (direct fusions) or reduced to 2 to 4 amino acids can be constructed as described below. Similar methods can be used to create linkers shorter than 7 amino acids, to create linkers longer than 7 amino acids and to create linkers containing other amino acid sequences. The experiments described below use IgG1-Fc and EPO and G-CSF as examples, however, similar procedures can be used for other GF or IgG domains, and